- Home
- ANTX
as of 01-08-2026 3:15pm EST
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | MENLO PARK |
| Market Cap: | 31.2M | IPO Year: | 2022 |
| Target Price: | $2.00 | AVG Volume (30 days): | 57.8K |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.13 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.00 - $1.55 | Next Earning Date: | 11-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered ANTX Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of AN2 Therapeutics Inc. (ANTX)
Chief Development Officer
Avg Cost/Share
$1.01
Shares
5,956
Total Value
$6,027.47
Owned After
75,823
SEC Form 4
See Remarks
Avg Cost/Share
$1.01
Shares
6,931
Total Value
$7,014.17
Owned After
152,499
SEC Form 4
Chief Strategy Officer
Avg Cost/Share
$1.01
Shares
2,858
Total Value
$2,892.30
Owned After
59,086
SEC Form 4
Chief Development Officer
Avg Cost/Share
$1.00
Shares
3,295
Total Value
$3,304.88
Owned After
75,823
SEC Form 4
See Remarks
Avg Cost/Share
$1.00
Shares
17,923
Total Value
$17,948.09
Owned After
152,499
SEC Form 4
Chief Strategy Officer
Avg Cost/Share
$1.00
Shares
3,604
Total Value
$3,614.81
Owned After
59,086
SEC Form 4
See Remarks
Avg Cost/Share
$1.14
Shares
2,819
Total Value
$3,213.66
Owned After
152,499
SEC Form 4
Chief Strategy Officer
Avg Cost/Share
$1.14
Shares
765
Total Value
$872.10
Owned After
59,086
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Day Lucy | ANTX | Chief Financial Officer | Jan 6, 2026 | Sell | $1.01 | 5,512 | $5,578.14 | 75,363 | |
| Chanda Sanjay | ANTX | Chief Development Officer | Jan 6, 2026 | Sell | $1.01 | 5,956 | $6,027.47 | 75,823 | |
| Eizen Joshua M | ANTX | See Remarks | Jan 6, 2026 | Sell | $1.01 | 6,931 | $7,014.17 | 152,499 | |
| Prior Stephen David | ANTX | Chief Strategy Officer | Jan 6, 2026 | Sell | $1.01 | 2,858 | $2,892.30 | 59,086 | |
| Day Lucy | ANTX | Chief Financial Officer | Jan 5, 2026 | Sell | $1.00 | 3,295 | $3,304.88 | 75,363 | |
| Chanda Sanjay | ANTX | Chief Development Officer | Jan 5, 2026 | Sell | $1.00 | 3,295 | $3,304.88 | 75,823 | |
| Eizen Joshua M | ANTX | See Remarks | Jan 5, 2026 | Sell | $1.00 | 17,923 | $17,948.09 | 152,499 | |
| Prior Stephen David | ANTX | Chief Strategy Officer | Jan 5, 2026 | Sell | $1.00 | 3,604 | $3,614.81 | 59,086 | |
| Eizen Joshua M | ANTX | See Remarks | Nov 4, 2025 | Sell | $1.14 | 2,819 | $3,213.66 | 152,499 | |
| Prior Stephen David | ANTX | Chief Strategy Officer | Nov 4, 2025 | Sell | $1.14 | 765 | $872.10 | 59,086 |
Compare ANTX vs Leading Stocks
See how ANTX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ANTX AN2 Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.